Anixa Biosciences Inc (ANIX) director reports 16,000 share option exercise

Rhea-AI Filing Summary

Anixa Biosciences Inc director Lewis H. Titterton, Jr. reported an insider stock transaction. On 12/15/2025, he exercised an employee stock option granted on 02/18/2016 with an exercise price of $2.92 per share, acquiring 16,000 shares of Anixa Biosciences common stock through a transaction coded "M" (option exercise).

Following this transaction, Titterton directly beneficially owned 969,334 shares of Anixa Biosciences common stock. The option covered 16,000 underlying shares, and after the exercise the number of derivative securities reported for this option position was 0.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Titterton Lewis H jr

(Last) (First) (Middle)

C/O ANIXA BIOSCIENCES, INC.

3150 ALMADEN EXPRESSWAY, SUITE 250

(Street)

SAN JOSE, CA 95118

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Anixa Biosciences Inc [ ANIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/15/2025		M		16,000	A	$2.92	969,334	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option(1)	$2.92	12/15/2025		M			16,000	02/18/2016	02/18/2026	Common Stock	16,000	$0.00	0	D

Explanation of Responses:

1. Right-To-Buy, pursuant to a stock option grant dated February 18, 2016.

	/s/ Lewis H. Titterton, Jr.	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Anixa Biosciences (ANIX) disclose in this Form 4?

The filing reports that director Lewis H. Titterton, Jr. exercised an employee stock option on 12/15/2025, acquiring 16,000 shares of Anixa Biosciences common stock at $2.92 per share in a transaction coded "M" (option exercise).

How many Anixa Biosciences (ANIX) shares does the director own after the reported transaction?

After the option exercise, Lewis H. Titterton, Jr. is reported to beneficially own 969,334 shares of Anixa Biosciences common stock, held in direct ownership.

What were the terms of the stock option exercised by the Anixa Biosciences (ANIX) director?

The director exercised an employee stock option originally granted on 02/18/2016, with an exercise price of $2.92 per share. The option covered 16,000 underlying common shares and had an expiration date of 02/18/2026.

What transaction codes were used in the Anixa Biosciences (ANIX) Form 4?

The transaction is coded "M" in both the non-derivative and derivative tables, indicating the exercise or conversion of a derivative security (in this case, an employee stock option) into common stock.

Did the Anixa Biosciences (ANIX) director retain any of the reported stock options after the transaction?

No derivative securities are shown as remaining from this option position. The table lists 0 derivative securities beneficially owned following the transaction for the reported employee stock option covering 16,000 shares.

What explanation is provided for the Anixa Biosciences (ANIX) insider transaction?

The explanation states that the transaction reflects a Right-To-Buy pursuant to a stock option grant dated February 18, 2016, which the director exercised on 12/15/2025.